NCT03761121 is a NA clinical trial of Wave-CAIPI in Pediatric Low-grade Gliomas, sponsored by Boston Children's Hospital.

Who is sponsoring NCT03761121?

NCT03761121 is sponsored by Boston Children's Hospital.

What drugs are being tested in NCT03761121?

Interventions in NCT03761121: Wave-CAIPI.

What condition does NCT03761121 study?

NCT03761121 studies Pediatric Low-grade Gliomas.

Is NCT03761121 still recruiting?

NCT03761121 is currently recruiting now. Last updated 12 December 2025.

Last reviewed 2025-12-12 · How we verify

NCT03761121

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Developing Fast Pediatric Imaging

Recruiting now NA Last updated 12 December 2025

What this trial tests

NA trial testing Wave-CAIPI in Pediatric Low-grade Gliomas in 300 participants. Currently enrolling.

Timeline

15 April 2019

Primary endpoint
1 September 2027

1 March 2028

Quick facts

Lead sponsor	Boston Children's Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	300
Start date	15 April 2019
Primary completion	1 September 2027
Estimated completion	1 March 2028
Sites	3 locations across United States

Drugs / interventions tested

Wave-CAIPI

Conditions studied

Pediatric Low-grade Gliomas — all drugs for Pediatric Low-grade Gliomas →

Sponsor

Boston Children's Hospital

Who can join

0 and older, any sex, with Pediatric Low-grade Gliomas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is evaluating the investigational software for magnetic resonance imaging (MRI) systems and techniques to process magnetic resonance (MR) images

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A systematic review of ongoing clinical trials in optic pathway gliomas.
Hill CS, Devesa SC, Ince W, Borg A, et al · · 2020 · cited 19× · PMID 32556546 · DOI 10.1007/s00381-020-04724-1

Verify or expand the search:

Other Boston Children's Hospital trials

Trials by the same sponsor.

NCT06804382 — Academic Detailing to Optimize PrEP Implementation in Pediatric Primary Care Settings: ADOPT-PrEP · NA · not yet recruiting
NCT05113394 — Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy · Phase 2 · withdrawn
NCT06434220 — Effect of Predictive Model on ED Physician Assessments of Patient Disposition · NA · not yet recruiting
NCT07476430 — Readiness Outcomes Affecting Return to Sport 3.0 · NA · not yet recruiting
NCT06706336 — Radon Asthma Intervention Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03761121 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boston Children's Hospital
Last refreshed: 12 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03761121.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing